Tumor Biology

, Volume 35, Issue 10, pp 9893–9896 | Cite as

Prognostic effect of p53 expression in patients with completely resected colorectal cancer

  • Bin-Wei Liu
  • Yang Liu
  • Jun-Ru Liu
  • Zhong-Xu Feng
  • Tong Liu
Research Article


The p53 protein is closely involved in the carcinogenesis of many kinds of cancers. Though the prognostic role of p53 expression for the survival of colorectal cancer (CRC) patients has been preliminarily identified, the prognostic effect of p53 expression in patients with completely resected CRC is still unclear. Therefore, a retrospective cohort study was performed to assess the prognostic role of p53 expression for overall survival in patients with completely resected CRC. A total of 153 patients (mean age 50.9 years) with completely resected CRC was finally included in the retrospective cohort study. Kaplan-Meier product-limit methods and log-rank test were used to estimate overall survival distribution and test the difference. In addition, multivariable analysis by Cox regression model was also used to test the prognostic role of p53 expression on overall survival by adjusting for other confounding factors. Of those 153 CRC patients, 62 (40.5 %) were positive for p53 protein expression in the tumor tissues. The log-rank test showed that there was an obvious difference in the overall survival between the p53-positive group and the p53-negative group (P < 0.001). Multivariable analysis by Cox regression model further showed that p53 protein expression was an independent predictor of shorter overall survival in patients with completely resected CRC (hazard ratio [HR] = 1.77; 95 % confidence interval [95 % CI] 1.15–2.71, P = 0.009). Therefore, p53 protein expression in the tumor tissue is an independent predictor of shorter overall survival in patients with completely resected CRC.


Colorectal cancer p53 protein Prognosis 


Conflicts of interest



  1. 1.
    Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375(9719):1030–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Peng H, Xie SK, Huang MJ, Ren DL. Associations of CYP2E1 rs2031920 nd rs383867 polymorphisms with colorectal cancer risk: a systemic review and meta-analysis. Tumor Biol. 2013;34(4):2389–95.CrossRefGoogle Scholar
  3. 3.
    Pfister DG, Benson 3rd AB, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350(23):2375–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Custodio A, Barriuso J, de Castro J, Martinez-Marin V, Moreno V, Rodriguez-Salas N, et al. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev. 2013;39(8):908–24.CrossRefPubMedGoogle Scholar
  5. 5.
    Guo Q, Dai SB, Shen F, Yu D, Shen ST, Zhang Q, et al. VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis. Tumor Biol. 2014;35(5):4977–82.CrossRefGoogle Scholar
  6. 6.
    Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010;468(7323):572–5.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microrna processing by p53. Nature. 2009;460(7254):529–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, et al. Increases in p53 expression induce ctgf synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest. 2011;121(8):3343–56.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ye Z, Cao Q, Niu G, Liang Y, Liu Y, Jiang L, et al. P63 and p53 expression in extranodal nk/t cell lymphoma, nasal type. J Clin Pathol. 2013;66(8):676–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT. Promoter methylation of igfbp-3 and p53 expression in ovarian endometrioid carcinoma. Mol Cancer. 2009;8(1):120.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage iii colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Malhotra P, Anwar M, Nanda N, Kochhar R, Wig JD, Vaiphei K, et al. Alterations in K-ras, APC and p53-mulptile genetic pathway in colorectal cancer among Indians. Tumor Biol. 2013;34(3):1901–11.CrossRefGoogle Scholar
  13. 13.
    Ueda Y, Yasuda K, Inomata M, Shiraishi N, Yokoyama S, Kitano S. Biological predictors of survival in stage ii colorectal cancer. Mol Clin Oncol. 2013;1(4):643–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, et al. Hormone receptor status rather than her2 status is significantly associated with increased ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol. 2011;135(2):230–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Su WJ, Fang JS, Cheng F, Liu C, Zhou F, Zhang J. Rnf2/ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development. Proc Natl Acad Sci U S A. 2013;110(5):1720–5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cho SJ, Rossi A, Jung YS, Yan W, Liu G, Zhang J, et al. Ninjurin1, a target of p53, regulates p53 expression and p53-dependent cell survival, senescence, and radiation-induced mortality. Proc Natl Acad Sci U S A. 2013;110(5):9362–7.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jiang L, Tao C, He A. Prognostic significance of p53 expression in malignant bone tumors: a meta-analysis. Tumor Biol. 2013;34(2):1037–43.CrossRefGoogle Scholar
  18. 18.
    De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. Kras, braf, pik3ca, and pten mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.CrossRefPubMedGoogle Scholar
  19. 19.
    Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, et al. Prognostic significance of mucin and p53 expression in stage ib non-small cell lung cancer: a laboratory companion study to calgb 9633. J Thorac Oncol. 2010;5(6):810–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    He S, Liu F, Xie Z, Zu X, Xu W, Jiang Y. P-glycoprotein/mdr1 regulates pokemon gene transcription through p53 expression in human breast cancer cells. Int J Mol Sci. 2010;11(9):3309–051.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, et al. P53 expression in node-positive breast cancer patients: results from the cancer and leukemia group b 9344 trial (159905). Clin Cancer Res. 2011;17(15):5170–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Khaled HM, Bahnassy AA, Raafat AA, Zekri AR, Madboul MS, Mokhtar NM. Clinical significance of altered nm23-h1, egfr, rb and p53 expression in bilharzial bladder cancer. BMC Cancer. 2009;9(1):32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kim Y, Park H, Park D, Lee YS, Choe J, Hahn JH, et al. Cancer/testis antigen cage exerts negative regulation on p53 expression through hdac2 and confers resistance to anti-cancer drugs. J Biol Chem. 2010;285(34):25957–68.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zhang HT, Wang YL, Zhang J, Zhang QX. Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumor Biol. 2014;35(2):1403–9.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Bin-Wei Liu
    • 1
  • Yang Liu
    • 2
  • Jun-Ru Liu
    • 3
  • Zhong-Xu Feng
    • 2
  • Tong Liu
    • 1
  1. 1.Department of General SurgeryTianjin Medical University General HospitalTianjinChina
  2. 2.Department of General SurgeryQinhuangdao First HospitalQinhuangdaoChina
  3. 3.Department of EndocrinologyQinhuangdao First HospitalQinhuangdaoChina

Personalised recommendations